Abstract
The aim of this study was to evaluate the safety and efficacy of a new intragastric balloon (Elipse™ Balloon, Allurion Technologies, Natick, MA USA) not needing endoscopy. The balloon was swallowed under fluoroscopy in 38 consecutive patients (F/M 28/10, mean age 46.4±10.6years, mean weight 109.7±21.9kg, and mean body mass index (BMI) 38.6±6.7kg/m2). After 4months, the balloon spontaneously emptied and it was excreted through the digestive tract without upper endoscopy. There were no complications during balloon passage. After 16weeks, the mean weight loss was 12.7kg, mean percent excess weight loss was 26%, and mean BMI reduction was 4.2kg/m2. Total body weight loss was 11.6%. There was a significant reduction in major co-morbidities related to metabolic syndrome: blood pressure (p<0.02), waist circumference (p<0.002), triglycerides (p<0.0001), blood glucose (p<0.001), and HOMA-IR index (p<0.001). At the end of the treatment, 37 balloons were naturally excreted in the stool, and one balloon was endoscopically removed. The results of this study on 38 consecutive patients demonstrate that the Elipse™ Balloon is safe, effective, and very well accepted by patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
